-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TU-2218 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TU-2218 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TU-2218 in Solid Tumor Drug Details: NCE-401 (TU-2218, SKI-2218) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TU-2218 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TU-2218 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TU-2218 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: NCE-401 (TU-2218,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tanimilast in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tanimilast in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tanimilast in Asthma Drug Details: Tanimilast (CHF-6001) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MSDC-0160 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MSDC-0160 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MSDC-0160 in Type 2 Diabetes Drug Details: MSDC-0160 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tanimilast in Chronic Bronchitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tanimilast in Chronic Bronchitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tanimilast in Chronic Bronchitis Drug Details: Tanimilast (CHF-6001) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocedurenone in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocedurenone in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocedurenone in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tanimilast in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tanimilast in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tanimilast in Chronic Obstructive Pulmonary Disease (COPD) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Temuterkib in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Temuterkib in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Temuterkib in Metastatic Pancreatic Cancer Drug Details: LY-3214996 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crenigacestat in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crenigacestat in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crenigacestat in Relapsed Multiple Myeloma Drug Details: Crenigacestat (LY-3039478) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crenigacestat in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crenigacestat in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crenigacestat in Refractory Multiple Myeloma Drug Details: Crenigacestat (LY-3039478) is...